Will the FDA’s surprising peptide decision turn Hims & Hers into a multi-billion-dollar powerhouse, or is Wall Street right to stay cautious?
What did the Hims & Hers FDA panel decide?
The Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the 503A Bulk List. This list dictates which ingredients compounding pharmacies can legally use. BPC-157, a popular peptide known for muscle and injury repair, is the first of seven peptides being reviewed by the committee. While the panel’s vote is non-binding, it represents a major victory for Hims & Hers Health, which acquired a dedicated peptide manufacturing facility last year.
The decision surprised many market participants because staff scientists at the FDA had previously released briefing materials recommending against the inclusion of these peptides, citing potential safety risks and a lack of clinical research. This creates a fascinating dynamic as the Hims & Hers FDA regulatory battle unfolds in real-time, especially with Health and Human Services Secretary Robert F. Kennedy Jr. advocating for a pathway to regulated peptide access to combat black-market sales.
How does this ruling impact the Hims & Hers FDA outlook?
Peptides represent a massive untapped frontier for the telehealth industry. Michael Cherny, an analyst at Leerink Partners, estimates that the annual market for these compounding substances could reach $2.2 billion if regulators ultimately approve all seven reviewed peptides. Cherny notes that Hims & Hers Health is uniquely positioned to capture up to 20% of this market, which could translate into a substantial long-term boost to earnings.
However, the commercial rollout of a novel peptide platform is not without execution risks. Currently, the company derives the vast majority of its revenue from branded GLP-1 treatments—competing indirectly in the weight-loss space dominated by giants like Eli Lilly and Novo Nordisk—as well as hair loss solutions and other established wellness products, making peptides a speculative future growth driver rather than an immediate cash cow.
Why are Wall Street banks keeping a neutral stance?
Despite the positive regulatory momentum, major financial institutions are advising caution. Daniel Grosslight, an analyst at Citigroup, maintained a Neutral rating on the stock but raised the firm’s price target from $28 to $35, reflecting the improved regulatory outlook. Similarly, Leerink Partners kept its market-perform rating with a $25 price target, suggesting the stock may already be fully valued at current levels.
Adding to the skepticism, controversial industry figure Martin Shkreli announced on social media that he has taken a short position in the company, labeling peptides as “fake medicine” and warning against moving backward in clinical standards. This mix of optimism and skepticism is reflected in option markets, where a bullish whale trade recently targeted a $35 call option expiring in January 2027, even as short-term traders brace for volatility.
Related Coverage
The outcome is a positive catalyst for the stock since BPC-157 is likely one of the more commercially viable of the seven peptides being reviewed.— Michael Cherny, Analyst at Leerink Partners
For investors tracking the broader telehealth and biotech landscape, staying updated on regulatory shifts is essential. Our recent analysis on the Hims & Hers Health Forecast Jumps 8% on Analyst Upgrades explores how earlier analyst optimism began to outweigh regulatory uncertainties. Meanwhile, those looking for high-growth opportunities in the medical sector might also want to read about CRISPR Therapeutics CAR-T: Inside Cathie Wood’s Next $60B Biotech Boom to see how gene-editing pipelines are quietly positioning themselves to revolutionize cancer treatments and surprise Wall Street.
